☆ 4.6 Review

The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis

CLINICAL KIDNEY JOURNAL (2023)

Related references

Note: Only part of the references are listed.

Review Medicine, Research & Experimental

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

Sreya Bagchi et al.

Summary: This article highlights the significance of immune checkpoint inhibitors in cancer immunotherapy and the research findings on the changes in local and systemic immune cells after treatment. It emphasizes the need for understanding the requirements for an effective and safe antitumor immune response following ICI therapy.

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)

Add to Collection

Article Urology & Nephrology

Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study

Yoshinosuke Shimamura et al.

Summary: The study revealed that the use of Pembrolizumab and the presence of liver diseases are associated with a higher risk of developing acute kidney injury (ICPi-AKI) with immune checkpoint inhibitors (ICPis), but ICPi-AKI does not affect mortality rates.

CLINICAL AND EXPERIMENTAL NEPHROLOGY (2021)

Add to Collection

Review Immunology

Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials

Hamidreza Akhbariyoon et al.

Summary: Advances in cancer immunotherapy have led to the development of immune checkpoint inhibitors targeting CTLA4, PD1, and PD-L1, which have shown promise in activating T cells to kill cancer cells. Clinical trials of ICIs in various cancers, including HCC, RCC, HL, NHL, NSCLC, and HNSCC, have demonstrated potential to change the treatment landscape.

CLINICAL IMMUNOLOGY (2021)

Add to Collection

Review Oncology

Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis

Han Li et al.

Summary: Anti-PD-1/PD-L1 monoclonal antibodies can significantly increase nephrotoxicity in patients with solid tumors, especially when combined with chemotherapy.

INVESTIGATIONAL NEW DRUGS (2021)

Add to Collection

Article Oncology

Acute kidney injury in patients treated with immune checkpoint inhibitors

Shruti Gupta et al.

Summary: Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) is an important toxicity among cancer patients. Impaired renal function at baseline, PPI use, and extrarenal irAEs were associated with a higher risk of ICPi-AKI. Two-thirds of patients experienced renal recovery following ICPi-AKI, with corticosteroid treatment associated with improved recovery.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Editorial Material Surgery

MOOSE Reporting Guidelines for Meta-analyses of Observational Studies

Benjamin S. Brooke et al.

JAMA SURGERY (2021)

Add to Collection

Article Multidisciplinary Sciences

Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study

Marije S. Koks et al.

Summary: This study aimed to investigate the incidence, risk factors, renal outcomes, and mortality of AKI in patients receiving checkpoint inhibitors for cancer treatment. The study found that one third of AKI cases were associated with checkpoint inhibitors, with an overall incidence of 14.2%. Checkpoint inhibitor-associated AKI was mostly low-grade and resulted in persistent renal dysfunction in approximately 40% of patients. Patients with all-cause AKI had a twofold increased mortality risk, but checkpoint inhibitor-associated AKI did not increase mortality.

PLOS ONE (2021)

Add to Collection

Review Urology & Nephrology

Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?

Mark A. Perazella et al.

KIDNEY INTERNATIONAL (2020)

Add to Collection

Review Pharmacology & Pharmacy

Immune checkpoint inhibitors: a promising anticancer therapy

Sima Singh et al.

DRUG DISCOVERY TODAY (2020)

Add to Collection

Article Urology & Nephrology

Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study

Frank B. Cortazar et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)

Add to Collection

Review Medical Laboratory Technology

Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis

Mitchell S. von Itzstein et al.

CLINICAL CHEMISTRY (2020)

Add to Collection

Review Dermatology

Immune checkpoint inhibitor-related dermatologic adverse events

Amaris N. Geisler et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Article Oncology

Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes

Alejandro Meraz-Munoz et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Urology & Nephrology

Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors

Harish Seethapathy et al.

KIDNEY INTERNATIONAL REPORTS (2020)

Add to Collection

Review Urology & Nephrology

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events

Sandra M. Herrmann et al.

KIDNEY INTERNATIONAL REPORTS (2020)

Add to Collection

Review Immunology

The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?

Rossana Franzin et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Transplantation

Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis

Sandhya Manohar et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)

Add to Collection

Article Oncology

Cancer and the Immune System: The History and Background of Immunotherapy

Maura Abbott et al.

SEMINARS IN ONCOLOGY NURSING (2019)

Add to Collection

Article Urology & Nephrology

The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors

Harish Seethapathy et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)

Add to Collection

Article Oncology

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

Omar Mamlouk et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Urology & Nephrology

Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients

Anushree C. Shirali et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2016)

Add to Collection

Article Urology & Nephrology

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

Frank B. Cortazar et al.

KIDNEY INTERNATIONAL (2016)

Add to Collection

Letter Urology & Nephrology

Ipilimumab-associated minimal-change disease

Jason M. Kidd et al.

KIDNEY INTERNATIONAL (2016)

Add to Collection

Article Urology & Nephrology

Pemetrexed-induced acute kidney injury leading to chronic kidney disease

Sophie Chauvet et al.

CLINICAL NEPHROLOGY (2014)

Add to Collection

Article Oncology

Kidney injuries related to ipilimumab

Hassane Izzedine et al.

INVESTIGATIONAL NEW DRUGS (2014)

Add to Collection

Review Pharmacology & Pharmacy

Cancer immunotherapy: accomplishments to date and future promise

Karim Y. Helmy et al.

THERAPEUTIC DELIVERY (2013)

Add to Collection

Article Medicine, General & Internal

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

David Moher et al.

BMJ-BRITISH MEDICAL JOURNAL (2009)

Add to Collection

Article Medicine, General & Internal

Measuring inconsistency in meta-analyses

JPT Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.